

Regulatory Workshop on Clinical Trial Designs in Neuromyelitis Optica (NMO) and Spectrum Disorders

Methods to Manage Risk in a Placebo Trial

Susan VanMeter, MD

Sarah Kavanagh, MPH

GlaxoSmithKline

Risk Mitigation Strategies

- Choice of comparator
- Choice of primary endpoint
- Randomization ratio
- Independent Data Monitoring Committee (IDMC)
- Interim analysis
- Adaptive design options